首页> Journal of bone and mineral metabolism> Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.

Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan.

导出 LinkOut

翻译打印收藏纠错

第一作者： Toshitsugu,Sugimoto

第一单位： Internal Medicine, 1, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.

作者： Toshitsugu,Sugimoto ^[1] ; Daisuke,Inoue ^[2] ; Masayuki,Maehara ^[3] ; Ichiro,Oikawa ^[3] ; Takashi,Shigematsu ^[4] ; Yoshiki,Nishizawa ^[5]

作者单位： Internal Medicine, 1, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan. ^[1] Third Department of Medicine, Teikyo University Chiba Medical Center, 3426-3 Anesaki, Ichihara-shi, Chiba, 299-0111, Japan. inoued@med.teikyo-u.ac.jp. ^[2] EA Pharma Co., Ltd., 2-1-1 Irifune, Chuo-ku, Tokyo, 104-0042, Japan. ^[3] Department of Nephrology, Wakayama Medical University, 811-1 Kimiidera, Wakayama-shi, Wakayama, 641-8509, Japan. ^[4] Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka, 545-8585, Japan.;Inoue Hospital, 16-17 Enoki-cho, Suita-shi, Osaka, 564-0053, Japan. ^[5]

关键词 Bisphosphonate Chronic kidney disease Once-monthly risedronate Renal safety eGFR